Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yixin Wan is a traditional Chinese medicine (TCM) pill developed and manufactured by Jiangxi Wannianqing Pharmaceutical. It is primarily indicated for the treatment of coronary heart disease and angina pectoris. The formulation typically contains a complex mixture of ingredients, including Ginseng, Artificial Musk, Bear Gall powder, Toad Venom (Chansu), Pearl, and Borneol. Its pharmacological actions are characterized by cardiotonic effects, increasing coronary blood flow, and improving myocardial oxygen supply. Specifically, the bufadienolides found in Toad Venom act as inhibitors of the sodium/potassium-transporting ATPase, thereby increasing myocardial contractility. Ginsenosides from Ginseng provide additional cardioprotective and anti-ischemic benefits. In TCM theory, it is used to tonify Qi, nourish the heart, and promote blood circulation to resolve stasis, addressing symptoms such as chest tightness, palpitations, and shortness of breath.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yixin wan.